Top Markets
#1 Wrapped One Wrapped One +14,737.38%
#2 Wrapped STX (Velar) Wrapped STX (Velar) +2,972.21%
#3 DeFi Kingdoms DeFi Kingdoms +1,091.73%
#4 Black Phoenix Black Phoenix +335.34%
#5 aPriori aPriori +115.80%
#6 Bedrock Bedrock +73.38%
#7 Cysic Cysic +44.55%
#8 Prom Prom +41.94%
#9 COTI COTI +35.38%
#10 Playnance Playnance +34.37%
Coin of the day
Wrapped One Wrapped One
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Arch Therapeutics, Inc. Arch Therapeutics, Inc.

Arch Therapeutics, Inc.

ARTH
Rang in Aktien #42478
Arch Therapeutics, Inc., operating alongside its affiliated companies,... Arch Therapeutics, Inc., operating alongside its affiliated companies, functions as a biotechnology firm within the United States. The organization focuses on developing and commercializing products derived from its unique AC5 self-assembling technology platform. These innovations are engineered to arrest bleeding, control fluid leakage, and assist in wound care during surgical interventions, following trauma, throughout interventional medical procedures, or in cases of disease. Its leading products, the AC5 advanced wound system and the AC5 topical hemostat, are specifically designed for application on the skin, proving effective for managing intricate chronic wounds or acute surgical injuries. The company was established in 2006 and is headquartered in Framingham, Massachusetts.
Aktienkurs
$0.0009
Zuletzt synchronisiert: 2025-05-27
Marktkapitalisierung
$1.15K
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Arch Therapeutics, Inc. (ARTH)

Kategorie

Healthcare
P/B-Verhältnis für Arch Therapeutics, Inc. (ARTH)
P/B-Verhältnis zum August 2026 TTM: 0.00
Laut den neuesten Finanzberichten und dem Aktienkurs von Arch Therapeutics, Inc. beträgt das aktuelle Kurs-Buchwert-Verhältnis (TTM) 0.00. Am Ende des Jahres 2022 lag das P/B-Verhältnis bei -1.10.
P/B-Verlauf für Arch Therapeutics, Inc. von 2011 bis 2026
P/B-Verhältnis zum Jahresende
Jahr P/B-Verhältnis ändert
2026 (TTM) 0.00 -100.00%
2023 -0.53 -51.55%
2022 -1.10 -96.06%
2021 -27.88 -99.36%
2020 -4.34K -56.09%
2019 -9.89K -210.08%
2018 8.98K -13.48%
2017 10.38K 98.71%
2016 5.23K 86.57%
2015 2.80K -894.57%
2014 -352.52 -102.95%
2013 11.96K -115.55%
2012 -76.90K -630.43%
2011 14.50K 0.00%
P/B-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/B-Verhältnis P/B-Verhältnis-Differenz Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.2613 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.3483 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 3.634 -
BE
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR